HW241045
/ Humanwell Healthcare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 14, 2025
Recently, Wuhan Renfu Innovative Drug R&D Center Co., Ltd., a subsidiary of Renfu Pharmaceutical Group, obtained the “Drug Clinical Trial Approval Notice“ for HW241045 tablets approved and issued by the National Medical Products Administration, approving the conduct of clinical trials for the treatment of idiopathic pulmonary fibrosis [Google translation]
(bydrug.pharmcube.com)
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1